Cadrenal Therapeutics, Inc. (CVKD) AI Stock Analysis

• Market Cap: $25.87M
• Dividend Yield: N/A
• Average Volume (3M): 27.37K
• Price to Earnings (P/E): ―
• Beta (1Y): 1.21
• Revenue Growth: N/A
• EPS Growth: -40.70%
• Country: US
• Employees: 4
• Sector: Healthcare
• Sector Strength: 45
• Industry: Biotechnology
• EPS (TTM): -1.87
• Shares Outstanding: 2,046,854
• 10 Day Avg. Volume: 23,971
• 30 Day Avg. Volume: 27,366
• PEG Ratio: N/A
• Price to Book (P/B): N/A
• Price to Sales (P/S): N/A
• P/FCF Ratio: N/A
• Enterprise Value/Market Cap: 0.70
• Enterprise Value/Revenue: 8.47K
• Enterprise Value/Gross Profit: -3.44K
• Enterprise Value/Ebitda: -1.28
• 1Y Price Target: $45.00
• Price Target Upside: 241.69% Upside
• Rating Consensus: Moderate Buy
• Number of Analyst Covering: 1

• Rating: 32 Underperform
• Price Target: ―

The overall score reflects significant financial challenges, including ongoing losses and no revenue generation, which weigh heavily on the company's outlook. Technical indicators suggest limited momentum, while valuation metrics highlight difficulties in assessing the stock's fair value. Despite a positive corporate development with the appointment of a new Chief Medical Officer, the fundamental financial weaknesses remain the dominant concern.

Positive Factors

Leadership Change

The appointment of Dr. James J. Ferguson as CMO is a strategic move that could enhance clinical development efforts, particularly in advancing the pivotal Phase 3 trial for tecarfarin, potentially strengthening the company's pipeline and addressing unmet medical needs.

Debt-Free Status

Operating without debt provides Cadrenal Therapeutics with greater financial flexibility and reduces the risk of financial distress, allowing the company to focus on strategic investments and R&D without the burden of interest obligations.

Strategic Partnerships

Engaging in strategic partnerships can provide additional revenue streams through licensing agreements and milestone payments, potentially accelerating product development and expanding market reach, which is crucial for a biotech firm with no current revenue.

Negative Factors

No Revenue Generation

The lack of revenue generation over an extended period highlights the company's reliance on external financing and poses significant challenges to achieving financial sustainability and profitability, impacting long-term viability.

Consistent Losses

Ongoing operational losses without a clear path to profitability indicate financial instability, which may hinder the company's ability to invest in R&D and expand its product pipeline, crucial for future growth in the biotech industry.

Negative Cash Flow

Negative cash flow from operations suggests that the company is not generating sufficient cash to cover its operational expenses, relying heavily on financing, which could limit its ability to sustain operations and invest in future growth.

Cadrenal Therapeutics, Inc. Business Overview & Revenue Model

Company Description

Cadrenal Therapeutics, Inc. operates as a clinical development biopharmaceutical company. The company focuses on developing Tecarfarin, a novel therapy with orphan drug indication for the prevention of systemic thromboembolism of cardiac origin in patients with end-stage renal disease and atrial fibrillation. The company was incorporated in 2022 and is headquartered in Ponte Vedra, Florida.

How the Company Makes Money

Cadrenal Therapeutics makes money primarily through the development and commercialization of proprietary pharmaceuticals. Revenue is generated from the sale of these drugs once they receive regulatory approval and are brought to market. Additionally, the company may engage in strategic partnerships and collaborations with other pharmaceutical firms, which can provide additional revenue streams through licensing agreements, milestone payments, and royalties. These partnerships can also help Cadrenal Therapeutics expand its market reach and accelerate the development of its product pipeline.

Cadrenal Therapeutics, Inc. Financial Statement Overview

Summary

Cadrenal Therapeutics, Inc. exhibits financial challenges with no revenue generation and consistent losses over the past three years. The company relies heavily on financing to maintain operations, with no clear path to revenue or profit generation. While the absence of debt is a positive factor, the lack of operational cash flow and ongoing losses are key concerns for long-term sustainability.

Income Statement

Cadrenal Therapeutics, Inc. has reported zero revenue over the past three years, indicating no operational sales or income. The company consistently reports negative EBIT and net income, highlighting ongoing operational losses without any revenue growth trajectory.

Balance Sheet

The company's balance sheet shows improvement in equity from negative to positive values, mainly due to financing activities. However, there is a lack of revenue generation and reliance on external financing. The absence of debt is positive, but the company is not generating income to strengthen its financial position.

Cash Flow

Cadrenal Therapeutics, Inc. shows negative free cash flow, indicating cash outflows exceeding inflows from operations. Operating cash flows are negative and increasing in magnitude, primarily supported by financing cash inflows. There is no cash flow generated from operations, posing sustainability challenges.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022
Income Statement
Total Revenue	2.13K	0.00	0.00	0.00
Gross Profit	-5.26K	-1.88K	-1.98K	-1.27K
EBITDA	-14.17M	-10.65M	-8.34M	-6.61M
Net Income	-10.44M	-10.65M	-8.36M	-6.71M
Balance Sheet
Total Assets	5.98M	10.12M	8.52M	778.17K
Cash, Cash Equivalents and Short-Term Investments	5.57M	10.02M	8.40M	32.59K
Total Debt	0.00	0.00	21.35K	640.71K
Total Liabilities	1.68M	2.68M	826.88K	6.33M
Stockholders Equity	4.30M	7.44M	7.69M	-5.55M
Cash Flow
Free Cash Flow	-11.67M	-7.36M	-3.53M	-1.20M
Operating Cash Flow	-11.67M	-7.36M	-3.53M	-1.20M
Investing Cash Flow	-6.54K	-6.54K	-3.25K	-2.28K
Financing Cash Flow	12.21M	8.98M	11.90M	1.24M

Cadrenal Therapeutics, Inc. Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 13.17
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Negative
• MACD: Positive
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For CVKD, the sentiment is Positive. The current price of 13.17 is above the 20-day moving average (MA) of 13.10, above the 50-day MA of 12.15, and below the 200-day MA of 15.03, indicating a neutral trend. The MACD of 0.25 indicates Positive momentum. The RSI at 52.92 is Neutral, neither overbought nor oversold. The STOCH value of 44.97 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for CVKD.

Cadrenal Therapeutics, Inc. Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
CASI	46 Neutral	27.58M	-0.59	-2120.91%	―	41.43%	-50.12%
LVTX	45 Neutral	39.06M	-1.41	-90.52%	―	-32.55%	-15.83%
KZR	42 Neutral	27.53M	-0.39	0.00%	―	-100.00%	28.44%
INKT	38 Underperform	68.25M	-5.31	0.00%	―	0.00%	41.90%
CVKD	32 Underperform	$25.87M	―	-340.31%	―	―	-40.70%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%

Cadrenal Therapeutics, Inc. Corporate Events

Cadrenal Therapeutics Appoints New Chief Medical Officer

On February 4, 2025, Cadrenal Therapeutics, Inc. appointed Dr. James J. Ferguson as its new Chief Medical Officer, effective February 5, 2025, following the mutually amicable departure of Dr. Douglas Losordo. Dr. Ferguson, with extensive experience in cardiovascular medicine, will lead the late-stage clinical development of tecarfarin, including a pivotal Phase 3 trial for LVAD patients. This leadership transition is expected to strengthen Cadrenal’s efforts in addressing unmet medical needs associated with standard warfarin therapy and enhance its pipeline of specialized cardiovascular treatments.